Carisbamate

Synonyms: RWJ-333369
Carisbamate (RWJ-333369) 是一种口服有效的神经调节剂,能防止癫痫样放电的发展和产生,在体外癫痫样损伤后具有神经保护作用,并在全身性惊厥性和非惊厥性癫痫的遗传模型中表现出较好的抗癫痫活性。
产品编号: MS-B21298 纯度: 98.75% CAS No.: 194085-75-1 分子式: C9H10ClNO3 分子量: 215.64
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Carisbamate (RWJ-333369) 是一种口服有效的神经调节剂,能防止癫痫样放电的发展和产生,在体外癫痫样损伤后具有神经保护作用,并在全身性惊厥性和非惊厥性癫痫的遗传模型中表现出较好的抗癫痫活性。

生物实验数据

生物活性 Carisbamate (RWJ-333369) is an orally effective neuromodulator that prevents the development and generation of epileptiform discharges, exerts neuroprotective effects after epileptiform injury in vitro, and demonstrates favorable antiepileptic activity in genetic models of generalized convulsive and non-convulsive epilepsy.
体外研究
(In Vitro)

Carisbamate (200 μM; 12 h) exhibits antiepileptic effects on SREDs model of hippocampal cells.
Carisbamate (200 μM; 24 h) shows long lasting effects on the hippocampal neurons that are independent from antiepileptic effects in vitro.
Carisbamate not only inhibits the development and expression of SREDs in the majority of neurons, but also decreases seizure frequency and duration in the few neurons that still has an occasional epileptiform event.
Carisbamate (200 μM) shows neuroprotective effects on hippocampal cells with SE (status epilepticus)-like injury.

Cell Viability Assay

Cell Line: Hippocampal cells (from 2-day postnatal Sprague-Dawley rat; spontaneous recurrent epileptiform discharges (SREDs) model)
Concentration: 200 µM
Incubation Time: 12 h
Result: Acutely inhibited SREDs with greater than 95% of the neurons exhibited an in vitro antiepileptic effect.

Cell Viability Assay

Cell Line: Hippocampal cells (SREDs model)
Concentration: 200 µM
Incubation Time: 24 h
Result: Exhibited cells evaluated the day after treatment were still free of in vitro seizure activity and did not develop SREDs.
体内研究
(In Vivo)

Carisbamate (10, 30, 60 mg/kg; i.p.; single) dose dependently reduces the expression of spike-and-wave discharges (SWD) in absence seizures rat model.
Carisbamate (20, 30 mg/kg; i.p.; single) shows no wild running episode or tonic seizure occurres in any of the rats tested.

Animal Model: Male genetic absence epilepsy rat (absence seizures model).
Dosage: 10, 30, 60 mg/kg
Administration: Intraperitoneal injection; single.
Result: Completely inhibited SWD when at 60 mg/kg after 120 min, and restored the duration of SWD to the control level when at 30 mg/kg after 100 min.
Animal Model: Male Wistar audiogenic sensitive rat (convulsive seizures model).
Dosage: 10, 20, 30 mg/kg
Administration: Intraperitoneal injection; single.
Result: Showed no wild running episode or tonic seizure occurred in any of the rats tested when at 20 and 30 mg/kg.
Increased by 327% the latency to the tonic seizure that still occurred in the six of eight rats studied when at 10 mg/kg.
性状 固体
颜色 White to off-white

化学信息

分子量 215.64
分子式 C9H10ClNO3
CAS No. 194085-75-1
别名 RWJ-333369

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 100 mg/mL (463.74 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM4.6374 mL23.1872 mL46.3744 mL115.9361 mL
5 mM0.9275 mL4.6374 mL9.2749 mL23.1872 mL
10 mM0.4637 mL2.3187 mL4.6374 mL11.5936 mL
15 mM0.3092 mL1.5458 mL3.0916 mL7.7291 mL
20 mM0.2319 mL1.1594 mL2.3187 mL5.7968 mL
25 mM0.1855 mL0.9275 mL1.8550 mL4.6374 mL
30 mM0.1546 mL0.7729 mL1.5458 mL3.8645 mL
40 mM0.1159 mL0.5797 mL1.1594 mL2.8984 mL
50 mM0.0927 mL0.4637 mL0.9275 mL2.3187 mL
60 mM0.0773 mL0.3865 mL0.7729 mL1.9323 mL
80 mM0.0580 mL0.2898 mL0.5797 mL1.4492 mL
100 mM0.0464 mL0.2319 mL0.4637 mL1.1594 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础